Tirofiban and SATIS

In August, the SATIS trial was finally published. After the disturbing results of AbESTT (or however it was spelled) this reintroduces GP IIb/IIIa antagonists into the stroke arsenal. Although the data look fine to me and I really use Tirofiban a lot, I wonder

  • The trial stopped enrolling 2008, since then the manuscript is “pending” according to clinicaltrials.gov
  • The manuscript was received in August 2010.

So what happened during all those years?

We discuss the publication and the pharmacology of Tirofiban.

What are the indications? The following is my personal opinion:

  • Lacunar stroke with fluctuating course
  • After thrombolysis AND recanalization
  • In high grade stenoses before intervention (say basilar artery stenosis)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.